The fate of an experimental dementia drug will be decided within days. On Monday, the Food and Drug Administration is set to announce whether it will approve Biogen’s antibody-based therapy aducanumab as a treatment for Alzheimer’s disease—the first intended to actually slow down the progression of the incurable…
via Gizmodo